The
following potential common share equivalents were excluded from the calculation of diluted net income per share because their effect
would have been anti-dilutive in the period presented (in thousands):
Schedule
of Antidilutive Securities Earnings Per Share
| | |
June 30, | | |
December 31, | |
| | |
2026 | | |
2025 | |
| Convertible preferred stock | |
| 936 | | |
| 1,040 | |
| Common Stock Warrants | |
| 383 | | |
| 1,321 | |
| Preferred Stock Warrants | |
| 13 | | |
| 13 | |
| Stock options | |
| 768 | | |
| 367 | |
| Total potential common stock excluded from net loss per share | |
| 2,100 | | |
| 2,741 | |
|
The
following potential common share equivalents were excluded from the calculation of diluted net income per share in FY 2025 because their
effect would have been anti-dilutive in the period presented (in thousands):
Schedule
of Antidilutive Securities Earnings Per Share
| | |
2025 | | |
2024 | |
| | |
Years Ended December 31, | |
| | |
2025 | | |
2024 | |
| Convertible preferred stock | |
| 1,040 | | |
| 1,328 | |
| Common Stock Warrants | |
| 1,321 | | |
| — | |
| Preferred Stock Warrants | |
| 13 | | |
| 13 | |
| Stock options | |
| 367 | | |
| 252 | |
| Total potential common stock excluded from net loss per share | |
| 2,741 | | |
| 1,593 | |
|